Inside Sana Biotechnology's plans to go public

Hollis Johnson/Business Insider


Well, we’ve made it to the final day of this year’s virtual J.P. Morgan Healthcare Conference. I’m nowhere near as exhausted as I usually am by the long days, but I am starting to miss actually bumping into people in San Francisco. What’s been your takeaway from the virtual conference? Let me know at [email protected].

And as we head toward the end of a busy week, I wanted to introduce you all to the newest member of the team, Allison DeAngelis! Say hi via email at [email protected] and follow her on Twitter at @ADeAngelis_bio.

Today in healthcare news: We read through Sana Biotechnology’s S-1 so you don’t have to, Ro’s getting into in-home, rapid coronavirus testing, and why one biotech VC predicts microbiome companies will take off in 2021.

Steve HarrJuno TherapeuticsSteve Harr

One of biotech’s most valuable startups just filed to go public. Here are 5 crucial takeaways from Sana’s 271-page filing.

Read the full story from Andrew Dunn and Allison DeAngelis here>>

Ro covid testRoRo will offer the Gauss COVID-19 antigen test on its site.

$US1.5 billion digital-health startup Ro wants to be your online doctor. Here’s how its coronavirus response rooted in rapid at-home testing fits into the new unicorn’s long-term strategy.

Read the full story from Megan Hernbroth here>>

Scientist examining bacterial culture plate.Getty Images

A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021

Read the full story from Patricia Kelly Yeo and Andrew Dunn here>>

More stories we’re reading:

– Lydia

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.